The capital return plan (up to ~$230M, ~25% of market cap) and the Pfizer/BioNTech LNP lawsuits are the primary catalysts. Monitor for the specific form of the tender offer/buyback and any developments in the international patent litigation. The imdusiran Phase 2b alignment is a positive pipeline de-risking event.
Price Chart
Executive Summary
Arbutus Biopharma reported Q2 2026 results with a net loss of $5.1M ($-0.03 EPS) vs net income of $2.5M ($0.01 EPS) in Q2 2025, driven by the absence of the prior year's $9.6M Qilu partnership revenue recognition. The company received $178.4M from the Moderna settlement in July and announced a plan to return up to ~$230M to shareholders via share repurchases, while also filing three international LNP patent lawsuits against Pfizer/BioNTech. The stock will move on the capital return plan and the Pfizer/BioNTech litigation catalyst, not the operational quarter.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $5.1M ($-0.03 EPS) vs net income of $2.5M ($0.01 EPS) in Q2 2025
- Total revenue fell to $1.0M from $10.7M YoY due to prior-year Qilu partnership revenue recognition
- Received $178.4M from Moderna settlement in July 2026
- Plans to return up to ~$230M to shareholders via share repurchases starting Q3 2026
- Filed three international LNP patent enforcement lawsuits against Pfizer/BioNTech across 21 countries
- FDA alignment achieved on Phase 2b trial design for imdusiran in chronic hepatitis B
- Cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026
Financial Impact
Up to $230M capital return to shareholders; $178.4M Moderna settlement payment received; $1.3B contingent payment possible from Moderna; Pfizer/BioNTech LNP lawsuits with unquantified potential
Risk Factors
- Capital return plan is subject to board approval and may not occur
- Pfizer/BioNTech lawsuits are early-stage and face significant legal hurdles
- Moderna contingent payment of $1.3B depends on appellate ruling on 28 U.S.C. 1498
- Operating cash burn continues ($14.1M in H1 2026)
- Imdusiran remains in clinical development with no guarantee of regulatory approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-005442 |
| Document: f8k_081226.htm | 0001171843-26-005442 |
| Document: 0001171843-26-005442-index-headers.html | 0001171843-26-005442 |
| Document: 0001171843-26-005442-index.html | 0001171843-26-005442 |
| Document: 0001171843-26-005442.txt | 0001171843-26-005442 |
| 8-K Data (Synthetic) | 0001171843-26-005442 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | 8-K | $5.21 $5.00 | ▼ −4.03% | ▼ −3.50% | $4.45 (−14.59%) |
Aug 15, 2026 6w ago | Institutional Cluster | $4.71 $5.06 | ▲ +7.43% | ▲ +9.41% | $4.45 (−5.52%) |
Aug 12, 2026 7w ago | 8-K | $4.59 $5.12 | ▲ +11.55% | ▲ +13.44% | $4.45 (−3.05%) |
Aug 12, 2026 7w ago | Press Release | $4.59 $5.12 | ▲ +11.55% | ▲ +13.44% | $4.45 (−3.05%) |
Jul 16, 2026 11w ago | 8-K | $4.74 $4.58 | ▼ −3.38% | ▼ −6.99% | $4.45 (−6.12%) |
Jun 12, 2026 16w ago | Institutional Cluster | $4.26 $4.80 | ▲ +12.68% | ▲ +10.90% | $4.45 (+4.46%) |
May 13, 2026 20w ago | 8-K | $4.31 $4.29 | ▼ −0.46% | ▲ +0.15% | $4.45 (+3.25%) |
May 13, 2026 20w ago | Press Release | $4.31 $4.29 | ▼ −0.46% | ▲ +0.15% | $4.45 (+3.25%) |
Apr 15, 2026 24w ago | 8-K | $4.48 $4.31 | ▼ −3.79% | ▼ −9.84% | $4.45 (−0.67%) |
Mar 23, 2026 27w ago | Press Release | $4.42 $4.43 | ▲ +0.23% | ▼ −7.19% | $4.45 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access